


				U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No.1	U.S. Patent Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CP0	AA	5,786,180		König et al	07-28-1998	
						5 7
						Ŧ z M
						Sept O
						田 6 二
						500/290 C
)/2
						900
						· · · · · · · · · · · · · · · · · · ·

				FOREIG	IN PATENT DOCUMEN	TS						
		Foreign Patent Number				Date of Publication						
Examiner Initials*	Cite No.1	Cite No.1	Cite No. ¹	Cite No.1	Cite No. ¹	Office ³	Number	Kind Code ⁵ (if known)	of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
رچي	AB	EP	0 613 007	А3	Brems et al	08-31-1994						
_												
			v - 40									
				-								
-			· · · · · · · · · · · · · · · · · · ·	·-·								

Examiner Signature Date Considered 7 30 2003

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
دوي	AC	FRIEDLAND et al, "Development of an Anti-Aβ Monoclonal Antibody for In Vivo Imaging of Amyloid Angiopathy in Alzheimer's Disease", Mol Neurobiol 9(1-3):107-113 (1994)	
cs	AD)	WALKER et al, "Labelinig of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody", <u>J Neuropathol Exp Neurol</u> 53(4):377-383 (1994)	
:			
Examin Signatu		Luilo Date Considered 7/30/03	•

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

and the second s						
Complete if Known						
Application Number	09/441,140					
Filing Date	November 16, 1999					
First Named Inventor	Beka SOLOMON					
Group Art Unit	4642- KH7					
Examiner Name	G. Bansal NICHOLS					
Attorney Docket Number	SOLOMON=1R					

				U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
دى	AE	5,750,349	Α	Suzuki et al	05-12-1998	
ī	AF	5,753,624	А	McMichael et al	05-19-1998	
V	AG	5,851,996	А	Kline	12-22-1998	
ري	АН	5,955,317	А	Suzuki et al	09-21-1999	- E

				FOREIG	N PATENT DOCUMENT	rs		27
			Foreign Patent Nu	ımber	Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,	1
Examiner Initials*	Cite No. ¹	Office ³	Number	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	R fl. c
(Z)	Al	wo	95/31996	A1	MILKHAUS LABORATORY	11-30-1995		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	5	B
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²	
B	AJ	DELIMASTRO et al, "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", <u>Vaccine</u> 15(11):1276-1285 (1997)		
	AK	DODART et al, "Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model", Nat Neurosci 5(5):452-457 (2002) (published online April 8, 2002, pp. 1-6)		
	AL	JANUS et al, "Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease", Nature 408(6815):979-982 (2000)		,
	AM	MANOUTCHARIAN et al, "Phage Displayed Biomolecules As Preventive and Therapeutic Agents", <u>Curr Pharm Biotechnol</u> 2(3):217-223 (2001)		
	AN	MORGAN et al, "Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease" Nature 408(6815):982-985 (2000)		
	AO	SEUBERT et al, "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids", Nature 359(6393):325-327 (1992)		
1	AP	Elan Internet Press Release, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792", January 18, 2002 (www.elan.com/NewsRoom)		
CZ	AQ	Elan Internet Press Release, "Elan and Wyeth provide update on status of Alzheimer's collaboration", Maple C	EI	/
<i>ٽ</i> —		AUG	28	þ١

Examiner Signature Date Considered 7130 OF CH CENTER 600/2900

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ATENT & THE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known						
Application Number	09/441,140					
Filing Date	November 16, 1999					
First Named Inventor	Beka SOLOMON					
Group Art Unit	1042 1647					
Examiner Name	S-Ungar NICHOUS					
Attorney Docket Number	SOLOMON=1R					

Examiner	Cite No.1	U.S. Patent	Document			
Initiats*				Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or
490	I IND. 1	Number	Kind Code ² (if known)	of Cited Document	MM-DD-YYYY	Relevant Figures Appear
	AR	6,417,178	B1	Klunk et al	07-09-2002	
7	AS	6,284,221	B1	Schenk et al	09-04-2001	
	AT	6,262,335	B1	Hsiao et al	07-17-2001	,
	ΑU	6,114,133	-	Seubert et al	09-05-2000	
	AV	5,958,883		Snow	09-28-1999	
	AW	5,955,079	<u> </u>	Mond et al	09-21-1999	
	AX	5,877,399	-	Hsiao et al	03-02-1999	
	AY	5,869,093		Weiner et al	02-09-1999	
	AZ	5,869,054	-	Weiner et al	02-09-1999	<u> 0</u>
	ВА	5,849,298		Weiner et al	12-15-1998	- 9 . M
	ВВ	5,837,473	-	Maggio et al	11-17-1998	6 72
	вс	5,780,587	-	Potter	07-14-1998	
	BD	5,744,368		Goldgaber et al	04-28-1998	
	BE	5,736,142		Sette et al	04-07-1998	
	BF	5,733,547		Weiner et al	03-31-1998	
	BG	5,679,348		Nesburn et al	10-21-1997	
	вн	5,645,820		Hafler et al	07-08-1997	
	ВІ	5,641,474		Hafler et al	06-24-1997	-
	BJ	5,641,473	-	Hafler et al	06-24-1997	
	вк	5,612,486		McConlogue et al	03-18-1997	
	BL	5,605,811		Seubert et al	02-25-1997	
	ВМ	5,585,100	-	Mond et al	12-17-1997	
	BN	5,571,500		Hafter et al	11-05-1996	
	во	5,571,499		Hafler et al	11-05-1996	7
	BP	5,441,870		Seubert et al	08-15-1995	
	BQ	5,434,170		Andrulis, Jr.	07-18-1995	
	BR	5,387,742		Cordell	02-07-1995	-
	BS	5,270,165		Van Nostrand et al	12-14-1993	
	вт	5,231,170		Averback	07-27-1993	
	BU	5,231,000		Majocha et al	07-27-1993	7
	BV	5,220,013		Ponte et al	06-15-1993	-
	BW	5,208,036		Eppstein et al	05-04-1993	
	вх	5,192,753		McGeer et al	03-09-1993	
	BY	5,187,153		Cordell et al	03-09-1993	
<u> </u>	BZ	5,057,540		Kensil et al	10-15-1991	7
V	CA	5,004,697		Pardridge	04-20-1991	,
an	СВ	4,666,829		Glenner et al	05-19-1987	

Examiner Signature	Mine	Date Considered	7130/03

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation was ber. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

	The second secon	
C	omplete if Known	
Application Number	09/441,140	
Filing Date	November 16, 1999	
First Named Inventor	Beka SOLOMON	
Group Art Unit	1042 (647	
Examiner Name	S. Ungar NICHOLS	
Attorney Docket Number	SOLOMON=1R	

					FOREIG	N PATENT DOCUMENTS			
Exan Initia	niner	Cite No.1	Office ³	Foreign Patent Numb	er Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
9	200	СС	wo	94/28412	A1	The Miriam Hospital	12-08-1994		
		CD	wo	94/03615	A1	Medeva Holdings B.V.	02-17-1994		
		CE	wo	94/01772	A1	Children's Med. Cen. Corp.	01-20-1994		
	\Box	CF	EP	0 276 723	B1	Bayer AG	12-08-1993		Yes
		CG	wo	93/21950	A1	Medeva Holdings B.V.	11-11-1993		
		СН	wo	93/16724	A1	Autoimmune, Inc.	09-02-1993		
		CI	wo	93/15760	A1	Mond et al	08-19-1993		
		CJ	wo	93/14200	A1	TSI Corporation	07-22-1993		
		СК	wo	93/04194	A1	Regents of U. of Minn.	03-04-1993		I
		CL	wo	93/02189	A1	Regents of U. of Cal.	02-04-1993		
	\prod	СМ	wo	92/13069	A1	Imp. Col. of Sci, Tech. & Med.	08-06-1992		
	$I \cup I$	CN	wo	92/06708	A1	Brigham and Women's Hosp.	04-30-1992		
		co	wo	92/06187	A1	The Upjohn Company	04-16-1992		
	\prod	CP	wo	91/19810	A1	California Biotechnology Inc.	12-26-1991	160	M
		CQ	wo	91/16819	A1	Molecular Rx, Inc.	11-14-1991	- 8 8	
		CR	EP	0 451 700	A1	Miles Inc.	10-16-1991		1
		cs	wo	91/12816	A1	Autoimmune, Inc.	09-05-1991		
		СТ	wo	91/08760	A1	Brigham and Women's Hosp.	06-27-1991		-
		CU	wo	90/12871	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990		-
		cv	wo	90/12870	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990		
		cw	GB	2 220 211	Α	Ribi Immunochem Research Inc.	01-04-1990		
П		сх	wo	89/06689	A1	McLean Hosp, Corp, & U. Roch.	07-27-1989		
		CY	wo	89/06242	A1	McLean Hosp, Corp. & U. Roch.	07-13-1989		
		cz	wo	89/03687	A1	Genetics Institute, Inc.	05-05-1989		
П		DA	wo	89/01343	A1	Regents of U. of Cal.	02-23-1989		
4	7	DB	wo	88/10120	A1	Brigham and Women's Hosp.	12-29-1988		
0	کے								

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
3	DC	BARROW et al, "Solution Conformations and Aggregational Properties of Synthetic Amyloid β-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <u>J Mol Biol</u> 225(4):1075-1093 (1992)	

Examiner Signature	a Mines	Date Considered	413do3	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Complete if Known Substitute for form 1449A/PTO 09/441,140 **Application Number** INFORMATION DISCLOSURE November 16, 1999 Filing Date Beka SOLOMON STATEMENT BY APPLICANT First Named Inventor Group Art Unit (use as many sheets as necessary) **Examiner Name**

		·					21011		
Sheet	3		of	8		Attorney Docket Number	SOLOMON=1R	300	
								ĬŽ	
جيو	DD	BAUER et al, "Interle 285(1):111-114 (199		and α-	2-macroglobulin	indicate an acute-phase state in A	Alzheimer's disease cortices," <u>F</u>	EBS Lett 8	
	DE BICKEL et al, "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," Soc for Neuroscience Abstracts 18:764 (325.6) (1992)								
	DF BODMER et al, "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem Biophys Res Comm</u> 171(2):890-897 (1990)								
DG BORIS-LAWRIE et al, "Recent advances in retrovirus vector technology," <u>Curr Opin Genet Dev</u> 3(1):102-109 (1993)						_			
DH BRICE et al, "Absence of the amyloid precursor protein gene mutation (APP717 : Val->lle) in 85 cases of early onset Alzheimer's disease," <u>J Neurol Neurosurg Psychiatry</u> 56:112-113 (1993)						t Alzheimer's			
DI CAPUTO et al, "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin Neuropharm 15(S1):414 415A (1992)						15(S1):414A-			
	DJ CHAO et al, "Transforming Growth Factor-β Protects Human Neurons Against β-Amyloid-Induced Injury,", 23 rd Annual Meeting, Washington, DC, November 7-12, 1993, Soc Neurosci Abstracts 19:513.7 (1993)					al Meeting,			
	DK CHEN et al "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," Neurosci Lett 125(2):223-226 (1991)					l Types,"			
	DL	CORDELL B "β-Amyl (1994)	loid fo	rmation	as a potential th	erapeutic target for Alzheimer's d	isease," <u>An. Rev Pharmacol To</u>	<u>xicol</u> 34:69-89	
	DM	COSTA et al, "Immui	noass	ay for tra	ansthyretin varia	nts associated with amyloid neuro	pathy," <u>Scand J Immunol</u> 38:17	7-182 (1993)	
	DN	ELIZAN et al, "Antine (1983)	eurofila	ament a	ntibodies in a po	stencephalitic and idiopathic Park	inson's disease," <u>J Neurol Sci</u> 5	9(3):341-347	_
	DO	FELSENSTEIN et al, terminal mutation," N				precursor protein carrying the fan 3)	nilial, Dutch-type, and a novel re	ecombinant C-	
	DP	FISHER et al, "Expre 1782 (1991)	ssion	of the a	myloid precurso	r protein gene in mouse oocytes a	and embryos," <u>Proc Natl Acad S</u>	<u>ci</u> 88:1779-	_
~ \	DQ	GANDY et al, "Amylo	oidoge	nesis in	Alzheimer's disc	ease: some possible therapeutic o	opportunities," <u>TiPS</u> 13:108-113	(1992)	

	Examiner Signature	6-Wilto	Date Considered	713003
--	-----------------------	---------	--------------------	--------

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Sheet

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

O9/441,140

Filing Date

November 16, 1999

First Named Inventor

Group Art Unit

Examiner Name

Subgar

OCHOCK

Attorney Docket Number

SOLOMON=1R

	_	DR	GARDELLA et al, "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem Biophys Res Comm</u> 173:1292-1298 (1990)	
6	7			
		DS	GASKIN et al, "Human antibodies reactive with β-amyloid protein in Alzheimer's disease," <u>J Exp Med</u> 177:1181-1186 (1993)	
۱ ۱				
		DT	GLENNER et al, "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochem Biophys Res Comm</u> 120(3):885-890 (1984)	
		DU	GLENNER et al, "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochem Biophys Res Comm</u> 122(3): 1131-1135 (1984)	
		DV	GOATE et al, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature 349:704-706 (1991)	
		DW	GORTNER, <u>Outlines of Biochemistry</u> , 3 rd Ed, Gorner et al Eds., John Wiley & Sons, Inc New York, pp. 322-323, (1949)	
'				
		DX	HAASS et al "Amyloid β-peptide is produced by cultured cells during normal metabolism," Nature 359(6393):322-5 (1992)	
	\setminus			
		DY	HAGA et al, "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Res</u> 601:88-94 (1993)	
	+	DZ	HARRINGTON et al. "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a	
:		02	monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β/A4-protein," <u>Biochim Biophys Acta</u> 1158(2):120-128 (1993)	
	H	EA	HAZAMA et al, "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused	-
ŀ			With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology 78:643-649 (1993)	
		EB	HILBICH et al, "Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized	
			in buffers of pH 7.4," <u>Eur J Biochem</u> 201:61-69 (1991)	
		EC	HUBERMAN et al, "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," Neuroimmunol 52(2):147-152 (1994)	
			<u> Newtonning 32(2). 141-132 (1334)</u>	
		ED	IKEDA et al, "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β	
N	 /		protein monoclonal antibody," <u>Lab Invest</u> 57(4):446-449 (1987)	
C	Co	EE	ITAGAKI et al, "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J Neuroimmunol</u> 24:173-182 (1989)	
7	ٔ ح			

Examiner Signature	Comme	Date Considered 7130(03	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

11 10/08/37 (10/30)	1	PTO/SB/57	(10/96)
---------------------	---	-----------	---------

ubstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 .of | 8

	Complete if Known	3	10	m
Application Number	09/441,140	T		C
Filing Date	November 16, 19	999	හා.	П
First Named Inventor	Beka SOLOMON	I ==	2	1
Group Art Unit	7042-1647		າດ	m
Examiner Name	S. Lingar 101	ato	9C.S	Ö
Attorney Docket Numbe	r SOLOMON=1R	(<u>C</u>)		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
9	EF	IWATSUBO et al, "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," Neuron 13:45-53 (1994)	
	EG	JANSEN et al, "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immunol Rev 62:185-216 (1982)	
	EH	JOACHIM et al, "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," Am J Pathol 138(2):373-384 (1991)	
	EI	KALARIA RN, "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res Immunol 143:637-641 (1992)	
	EJ	KAWABATA et al, "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature 354:476-478 (1991)	_
	EK	LAMPERT-ETCHELLS et al, "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993)	
	EL	LANGER, "New Methods of Drug Delivery," Science 249:1527-1532 (1990)	
	EM	LANNFELT et al, "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behav Brain Res</u> 57(2):207-213 (1993)	
	EN	LOPEZ et al, "Serum auto-antibodies in Alzheimer's disease," <u>Acta Neurol Scand</u> 84(5):441-444 (1991)	
	EO	MAJOCHA et al, "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy," <u>J Nuc Med</u> 33:2184-2189 (1992)	_
	EP	MAK et al, "Polyclonals to β-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Res</u> 667:138-142 (1994)	
C3	EQ	MASTERS et al, "Amyloid plaque core protein in Alzheimer disease and Down syndrome," <u>Proc Natl Acad Sci USA</u> 82:4245-4249 (1985)	_

Examiner Signature	6	Mielo-	Date Considered	7/30/03

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Complete if Known Substitute for form 1449A/PTO 09/441,140 **Application Number** INFORMATION DISCLOSURE Filing Date November 16, 1999 Beka SOLOMON STATEMENT BY APPLICANT **First Named Inventor** 1642 (Uft **Group Art Unit** (use as many sheets as necessary) **Examiner Name** Sheet 6 of 8 Attorney Docket Number SOLOMON=1R

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Κ.	ER)	McGEER et al, "Immunohistochemical Localization of Beta-Amyloid Precursor Protein Sequences in Alzheimer and Normal Brain Tissue by Light and Electron Microscopy," <u>J Neurosci Res</u> 31:428-442 (1992)	
	ES	MILLER et al, "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J Exp Med</u> 174:791-798 (1991)	
	ET	MORI et al, "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J Biol Chem</u> 267(24):17082-17088 (1992)	
	EU	MORRIS et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)," Neurology 39:1159-1165 (1989)	
	EV	MURPHY et al, "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am J Pathol</u> 144(5):1082-1088 (1994)	
	EW	NEWCOMBE et al, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim Biophys Acta</u> 104:480-486 (1965)	~
	EX	PARDRIDGE et al, "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem Biophys Res Comm</u> 146:307-313 (1987)	
	EY	PRIEELS et al, "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994)	
	EZ	QUON et al, "Formation of β-Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> 352:239-241 (1991)	
	FA	ROGERS et al, "Complement activation by β-amyloid in Alzheimer Disease," <u>Proc Natl Acad Sci USA,</u> 89:1-5 (1992)	
	FB	ROSSOR et al, "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Ann of NY Acad Sci</u> , 695:198-202 (1993)	
<i>∀</i> 30	FC	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976)	
		ER ES ES ET EU EV EW EX FA FB	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published ER McGEER et al, "Immunohistochemical Localization of Beta-Amyloid Precursor Protein Sequences in Alzheimer and Normal Brain Tissue by Light and Electron Microscopy," J.Neurosci.Res 31:428-442 (1992) ES MILLER et al, "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J.Exp. Med 174:791-798 (1991) ET MORI et al, "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J.Biol Chem 267(24):17082-17088 (1992) EU MORRIS et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)," Neurology 39:1159-1165 (1989) EV MURPHY et al, "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and its immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J.Pathol 144(5):1082-1088 (1994) EW NEWCOMBE et al, "Solubility characteristics of isolated amyloid fibrils," Biochim Biophys Acta 104:480-486 (1965) EX PARDRIDGE et al, "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," Biochem Biophys Res Comm 146:307-313 (1987) EY PRIEELS et al, "Synergistic adjuvants for vaccines," Chemical Abstracts, 120(8): pg. 652, column 1, abstract 86406t (1994) EZ QUON et al, "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature 352:239-241 (1991) FA ROGERS et al, "Camplement activation by β-amyloid in Alzheimer Disease," Proc Natl Acad Sci. 89:1-5 (1992) FB ROSSOR et al, "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Ann of NY Acad Sci. 695:198-202 FFC RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in Peptide Hormones, J.A.

Examiner Signature	(Niels	Date Considered 71300	03
			

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.


Complete if Known ubstitute for form 1449A/PTO 09/441,140 **Application Number** INFORMATION DISCLOSURE November 16, 1999 Filing Date Beka SOLOMON STATEMENT BY APPLICANT **First Named Inventor** Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheet 7 of 8 Attorney Docket Number SOLOMON=1R

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
FD	SAIDO et al, "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J Biol Chem</u> 269(21):15253-15257 (1994)	
FE	SAIDO et al, "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J Biol Chem</u> 268(33):25239-25243 (1993)	
FF	SAITOH et al, "Immunological Analysis of Alzheimer's Disease Using Anti-β-protein Monoclonal Antibodies," <u>Sapporo Med J</u> 60:309-320 (1991)	_
FG	SELKOE DJ "Alzheimer's Disease: A Central Role for Amyloid," <u>J Neuropathol Exp Neurol</u> 53(5): 438-447 (1994)	_
FH	SELKOE DJ, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," <u>Trends Neurosci</u> , 16(10):403-409 (1993)	
FI	SELKOE DJ, "Alzheimer's disease. In the Beginning," Nature 354(6353):432-433 (1991)	NO
FJ	SELKOE DJ, "Amyloid Protein and Alzheimer's Disease," Sci Am 265(5):68-78 (1991)	1/5
FK	SELKOE DJ, "The Molecular pathology of Alzheimer's Disease," Neuron 6(4):487-498 (1991)	2002
FL	SHIOSAKA S "Attempts to make models for Alzheimer's disease," Neurosci Res 13(4):237-255 (1992)	_
FM	TRIEB et al, "Is Alzheimer β amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," !mmunobiology , 191(2-3):114-115 Abstract C.37 (1994)	_
FN	VAN GOOL et al, "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neurosci Lett 172:122-124 (1994)	
FO	VERBEEK et al, "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Am J Pathol 144(1):104-116 (1994)	
	FE FF F	Cite No. Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, (it) and/or country where published. FD SAIDO et al, "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," J.Biol.Chem 269(21):15253-15257 (1994) FE SAIDO et al, "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J.Biol.Chem 268(33):25239-25243 (1993) FF SAITOH et al, "Immunological Analysis of Alzheimer's Disease Using Anti-β-protein Monoclonal Antibodies," Sapporo Med. J. 60:309-320 (1991) FG SELKOE DJ, "Alzheimer's Disease: A Central Role for Amyloid," J.Neuropathol.Exp.Neurol.53(5): 438-447 (1994) FH SELKOE DJ, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," Trends Neurosci. 16(10):403-409 (1993) FI SELKOE DJ, "Alzheimer's disease. In the Beginning," Nature 354(6353):432-433 (1991) FJ SELKOE DJ, "Amyloid Protein and Alzheimer's Disease," Sci.Am 265(5):68-78 (1991) FK SELKOE DJ, "The Molecular pathology of Alzheimer's Disease," Neuron 6(4):487-498 (1991) FK SELKOE DJ, "The Molecular pathology of Alzheimer's disease," Neurosci Res 13(4):237-255 (1992) FM TRIES et al, "Is Alzheimer β amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37 (1994) FN VAN GOOL et al, "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neurosci Lettl 172:122-124 (1994)

Examiner Signature	a Nierlo	Date Considered	7/30/03
			<u></u>

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 8

		_			
Complete if Known					
Application Number	09/441,140				
Filing Date	November 16, 1999				
First Named Inventor	Beka SOLOMON	_			
Group Art Unit	1642-1647				
Examiner Name	S. Ungar- 1016/1005				
Attorney Docket Number	SOLOMON=1R				

CA	(2)		WEINER et al, "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu Rev Immunol</u> 12:809-837 (1994)	
	-		WONG et al, "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>Proc NatlA cad Sci</u>	·
'			<u>USA</u> 82:8729-8732 (1985)	
		FR	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94)	
			Wisconsin Alumni Research Foundation, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their	
6			Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep 70(24), 56. (June 19, 1969)	_
4	Š		Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (1969)	_
,				
			ECH CEI	ם ת
			ENTER 5)=N
			NOV 1 5 2002 TECH CENTER 1600/2900	ED
			S	

Examiner Signature Date Considered 430/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.